For people taking an antidepressant, getting better is only half the goal. The other half is staying better. A new study offers doctors and patients more information about which medications may be most useful for both.
Researchers conducted what they describe as the first large-scale comparison of antidepressants looking at both short- and long-term effectiveness. The international research team analyzed evidence from 115 previously-conducted randomized clinical trials involving more than 30,000 people with depression. They compared 20 antidepressants with one another and with the antidepressant fluoxetine, better known as Prozac, that served as the comparison drug.
The study, published in The Lancet Psychiatry, was a systematic review and meta-analysis. This approach allows researchers to bring together results from many trials and compare medications even when some have not been tested directly against one another.Some antidepressants can do more than relieve symptoms in the short term: They can also help people remain well during longer-term treatment.
The findings suggest that some antidepressants can do more than relieve symptoms in the short term: They can also help people remain well during longer-term treatment.
There were meaningful differences found among selective serotonin reuptake inhibitors (SSRIs), a class of antidepressants commonly recommended as a first-line treatment.
Three drugs, escitalopram, sold as Lexapro; agomelatine, which is not FDA-approved for sale in the U.S.; and duloxetine, sold as Cymbalta, appeared to be more effective for long-term treatment than fluoxetine.
Among SSRIs, escitalopram appeared to be the most effective for long-term use.
The results do not mean that escitalopram, or any other medication, should automatically become the choice for everyone with depression, the researchers emphasize. Because antidepressants can differ in their side effects and suitability for a particular patient, treatment needs to be individualized.
The researchers do say their findings should inform the initial choice of an antidepressant when long-term treatment is anticipated. That matters because the decision to continue medication often comes after symptoms improve, when patients and clinicians are weighing the value of preventing relapse against the burden and possible side effects of taking a drug.Among SSRIs, escitalopram appeared to be the most effective antidepressant for long-term use.
The results also put fluoxetine in a different perspective. Because it is a well-known antidepressant, it provided a common benchmark for comparing medications. Finding differences among drugs suggests that antidepressants should not necessarily be viewed as interchangeable when clinicians are thinking about maintaining recovery.
For someone who is doing well on an antidepressant, these findings are not a reason to stop or switch medication without medical advice. Instead, the study presents another useful question for the next conversation with a doctor: Is this medication not only helping me feel better now, but also helping me stay well.



